Helix BioPharma Company Executives

Helix BioPharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.3036) % which means that it has lost $0.3036 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6635) %, meaning that it generated substantial loss on money invested by shareholders. Helix BioPharma's management efficiency ratios could be used to measure how well Helix BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of February 2026, Return On Tangible Assets is likely to grow to -13.77. In addition to that, Return On Capital Employed is likely to grow to -0.3. At this time, Helix BioPharma's Total Assets are very stable compared to the past year. As of the 2nd of February 2026, Non Current Assets Total is likely to grow to about 22.2 M, while Total Current Assets are likely to drop about 349.7 K. As of the 2nd of February 2026, Common Stock Shares Outstanding is likely to grow to about 67.3 M, while Net Loss is likely to drop (6.3 M). Helix BioPharma Corp has a total of 76.38 Million outstanding shares. Helix BioPharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Helix BioPharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Helix BioPharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Helix BioPharma Workforce Comparison

Helix BioPharma Corp Benchmark Summation

Helix BioPharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Helix BioPharma Corp often depends on how effective the management is. Helix BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Helix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Helix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.